Genmab drugs encounter European obstacles
Genmab’s commercial partners have both hit a snag in the European regulatory system, with one of them withdrawing an application for a Genmab-developed drug and another having to answer additional questions about a second Genmab-developed medicine.
BY STEFAN SINGH KAILAY
The resume of last week’s meeting of the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) did not exactly make for great reading for the Danish biotech company Genmab.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab CEO hails “landmark” approval
For abonnenter
